Diabetes News and Research

Latest Diabetes News and Research

Alimera Sciences second-quarter net loss decreases to $4.8 million

Alimera Sciences, Inc., today announced financial results for the second quarter ended June 30, 2010 and provided an update on progress toward achieving its 2010 goals.

13 Aug 2010

Interleukin Genetics, University of Michigan to conduct landmark clinical study on periodontal disease

Interleukin Genetics, Inc. announced today that the Company has signed an agreement with the University of Michigan to conduct a landmark clinical study on risk factors predictive of periodontal disease progression to tooth loss using a new version of Interleukin Genetics' PST genetic test.

12 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

Researchers have been able to use a common chaperone protein, Hsp70, to reverse the loss of function in the nerves of mice with diabetes.Writing in ASN NEURO, Michael J. Urban and colleagues at the University of Kansas suggest that Hsp70 could be used in the future to cure the loss of feeling in the limbs that afflicts many diabetics.

12 Aug 2010

Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement

Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.

12 Aug 2010

Reduced quality or quantity of sleep leads to school performance difficulties, behavior problems

Getting a good night's sleep often comes down to technique. Avoiding late-night technology use and keeping a regular sleep schedule are two important techniques to heed as kids head back to school.Recent studies found that adolescents used multiple forms of technology late into the night, including gaming systems, cell phones, and computers. As a result, they demonstrated difficulty staying awake and alert throughout the day.

12 Aug 2010

TriZetto announces general availability of health benefits administration and incentive management software

The TriZetto Group, Inc. today announced the general availability of its Value-Based Benefits Solution, health benefits administration and incentive management software that enables healthcare payers to customize benefits and provide incentives for individual members based on their health status, chronic conditions, and health and wellness activity.

12 Aug 2010

Wound Management Technologies introduces CellerateRX wound care collagen product in South Africa

Wound Management Technologies, Inc. is pleased to announce the sales expansion of its advanced wound care collagen product, CellerateRX, into South Africa. With EWA Government Systems and Spiramed (Pty) Ltd., the Company has obtained the registration of the product in the region and has also obtained the necessary NAPPI codes, which are a pre-requisite for any billable health product in South Africa. In addition, CellerateRX® is registered with various South African insurance companies and is an authorized product for reimbursement.

12 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

Researchers develop first diabetes risk assessment for multi-ethnic population

A team from the University of Leicester, led by Professor Melanie Davies from the Department of Cardiovascular Sciences and Professor Kamlesh Khunti from the Department of Health Sciences, has developed an easy way for people to assess their risk of having diabetes. Working in partnership with Diabetes UK, the largest diabetes charity in the country, and University Hospitals of Leicester NHS Trust, they have produced the first diabetes risk assessment that can be used in a multi-ethnic population.

12 Aug 2010

Third round of tax-free $250 rebate checks mailed to eligible Medicare beneficiaries

Today, U.S. Department of Health and Human Services Secretary Kathleen Sebelius announced that the third round of one-time, tax-free $250 rebate checks have been mailed to eligible Medicare beneficiaries whose drug costs are so high they have reached the Medicare Part D prescription drug coverage gap known as the "donut hole."

11 Aug 2010

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes

Depomed, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design and analysis of Breeze 3, a Phase 3 trial evaluating Serada® (extended release gabapentin tablets) for menopausal hot flashes.

11 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

Researchers receive $1M grant to train Native American communities improve their health

UC Davis School of Medicine researchers will train Native American communities in Northern California to develop and implement culturally appropriate interventions to improve their health by decreasing obesity and type-2 diabetes, through a $1 million research grant from the National Institute of Diabetes and Kidney Diseases of the National Institutes of Health.

11 Aug 2010

NKTreg white blood cells migrate into liver, suppress immune responses: Research

After a transplant - and to assure that the new organ is not rejected - patients are put on life-long therapy to suppress their immune system, which, nevertheless, needs to be left intact enough to be able to defend the body against all kinds of disease. A tricky balance as the many rejected organs attest. But a discovery by Maria Monteiro and Luis Graça, two Portuguese scientists, could change all this, at least for the liver.

11 Aug 2010

Entelos receives patent for PhysioLab virtual patient technology

Entelos, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,774,182, entitled "Apparatus and Method for Validating a Computer Model." This patent was issued to Entelos for its invention of an innovative computer-implemented method for validating multiple virtual patients within a computer model. The PhysioLab virtual patient technology allows Entelos life scientists and engineers to more rapidly evaluate the safety and efficacy of new therapeutics in a diverse population of patients. This predictive power is integrated into our PhysioLab platforms, which have been used by our pharmaceutical and consumer product customers for over a decade to dramatically reduce the risk, time, and cost of product development.

11 Aug 2010

Survey finds prevalence of diabetic retinopathy high among U.S. adults

Nearly 30 percent of U.S. adults with diabetes over the age of 40 are estimated to have diabetic retinopathy, with about 4 percent of this population having vision-threatening retinopathy, according to a study in the August 11 issue of JAMA.

11 Aug 2010

Dems continue push to sell health reform's benefits, GOP pushes back

The administration has struggled to sell senior citizens on the new health law, Politico reports. Here's why: "They know little about the early benefits the law has offered but remember last year's heated town halls, replete with death panels and rationing. And anti-health-reform rhetoric is generally proving to have considerable staying power."

11 Aug 2010

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval

Novo Nordisk announced today that the U.S. Food and Drug Administration has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation and administration of this medication for those patients who need a larger dose. In addition, FDA has also approved the extension of shelf life for all vial sizes from 24 months to 36 months at room temperature (at or below 77 degrees Fahrenheit).

11 Aug 2010

Telephone monitoring can save heart failure patients: Study

Chronic heart failure needs constant care and regular monitoring. Now research says remote monitoring, either over the phone or using wireless technology, helps people with heart failure live longer and stay out of hospital.

10 Aug 2010

Diabetes News and Research

Latest Diabetes News and Research

Alimera Sciences second-quarter net loss decreases to $4.8 million

Interleukin Genetics, University of Michigan to conduct landmark clinical study on periodontal disease

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement

Reduced quality or quantity of sleep leads to school performance difficulties, behavior problems

TriZetto announces general availability of health benefits administration and incentive management software

Wound Management Technologies introduces CellerateRX wound care collagen product in South Africa

Intellect Neurosciences receives patent for insulin sensitizer drugs

Researchers develop first diabetes risk assessment for multi-ethnic population

Third round of tax-free $250 rebate checks mailed to eligible Medicare beneficiaries

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes

Repros receives US patent for Androxal

Researchers receive $1M grant to train Native American communities improve their health

NKTreg white blood cells migrate into liver, suppress immune responses: Research

Entelos receives patent for PhysioLab virtual patient technology

Survey finds prevalence of diabetic retinopathy high among U.S. adults

Dems continue push to sell health reform's benefits, GOP pushes back

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval

Telephone monitoring can save heart failure patients: Study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Diabetes News and Research

Latest Diabetes News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in